Gholamreza Askari

Dr. Gholamreza Askari


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2016 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
SRSepideh Rahmani
Sepideh Rahmani
SASedighe Asgary
Sedighe Asgary
GAGholamreza Askari
Gholamreza Askari
MKmahtab keshvari
mahtab keshvari
MHMahdi Hatamipour
Mahdi Hatamipour
ASAmirhossein Sahebkar
Amirhossein Sahebkar

21 August 2021 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
STSorour Taheriniya
Sorour Taheriniya
AAArman Arab
Arman Arab
AHAmir Hadi
Amir Hadi
AFAbdulmannan Fadel
Abdulmannan Fadel
GAGholamreza Askari
Gholamreza Askari
Background: The contribution of vitamin D to thyroid disorders has received paramount attention; however, results are mixed. Hence, we designed a systematic review and meta-analysis to obtain a definitive conclusion. Methods: The search included PubMed, ISI Web of Science, Scopus, and Google Scholar databases up to March 2021 to collect available papers reporting the relationship between serum levels of vitamin D and thyroid disorders. The pooled effect was reported as weighted mean difference (WMD) and 95% confidence interval (CI). Results: Out of 6123 datasets, 42 were eligible to get into this systematic review and meta-analysis. Serum vitamin D was markedly lower in autoimmune thyroid diseases (AITD) (WMD − 3.1 ng/dl; 95% CI, − 5.57 to − 0.66; P = 0.013; I2 = 99.9%), Hashimoto’s thyroiditis (HT) (WMD − 6.05 ng/dl; 95% CI, − 8.35 to − 3.75; P < 0.001; I2 = 91.0%) and hypothyroidism patients (WMD − 13.43 ng/dl; 95% CI, − 26.04 to − 0.81; P = 0.03; I2 = 99.5%), but not in subjects with Graves’ disease (GD) (WMD − 4.14 ng/dl; 95% CI, − 8.46 to 0.17; P = 0.06; I2 = 97.5%). Conclusions: Our findings suggested lower vitamin D levels in patients with hypothyroidism, AITD, and HT compared to healthy subjects. However, the link between serum vitamin D and GD was only significant among subjects ≥40 years old.

1 January 2015 in International Journal of Preventive Medicine
Verified
Journal Article
Open access
PDF file
GAGholamreza Askari
Gholamreza Askari
TSTanaz Shoaei
Tanaz Shoaei
MHMotahar Heidari-Beni
Motahar Heidari-Beni
HTHatav Ghasemi Tehrani
Hatav Ghasemi Tehrani
AFAwat Feizi
Awat Feizi
AEAhmad Esmaillzadeh
Ahmad Esmaillzadeh
Background: Polycystic ovary syndrome (PCOS) is a polygenic endocrine disorder in women of reproductive age that lead to infertility. The aim of this study was to investigate the effects of probiotic on pancreatic b-cell function and C-reactive protein (CRP) in PCOS patients. Methods: This randomized double-blind placebo-controlled clinical trial was conducted among 72 women aged 15-40 years old diagnosed with PCOS. Participants were randomly assigned to two groups receiving: (1) Probiotic supplements (n = 36), (2) placebo (n = 36) for 8-week. Fasting blood samples were taken at baseline and after 8-week of intervention. Results: Probiotic supplementation, compare with placebo, reduced fasting blood sugar (−4.15 ± 2.87 vs. 2.57 ± 5.66 mg/dL, respectively P = 0.7), serum insulin levels in crude model (−0.49 ± 0.67 vs. 0.34 ± 0.82 mIU/mL, respectively, P = 0.09), homeostasis model of assessment-insulin resistance score (−0.25 ± 0.18 vs. −0.05 ± 0.18, respectively, P = 0.14) nonsignificantly. Serum insulin levels after adjustment with covariates reduced significantly in probiotic group (P = 0.02). We did not found any significant differences in mean changes of CRP between groups (−0.25 ± 0.18 vs. −0.05 ± 0.18, respectively, P = 0.14). Conclusions: A 8-week multispecies probiotics supplementation had nonsignificantly beneficial effect on pancreatic b-cell function and CRP in PCOS patients. After adjustment for some covariates, serum insulin changes were significantly different between groups.

1 January 2016 in International Journal of Preventive Medicine
Verified
Journal Article
Open access
PDF file
GAGholamreza Askari
Gholamreza Askari
APAli Pezeshki
Ali Pezeshki
SSSara Safi
Sara Safi
AFAwat Feizi
Awat Feizi
FKFatemeh Karami
Fatemeh Karami
Background: Green tea is one of the most popular beverages in the world. It is believed to have beneficial effects in the prevention and treatment of many diseases, one of which is nonalcoholic fatty liver disease (NAFLD). The present study investigated the effects of consumption of green tea in NAFLD patients. Methods: This study was a double-blind, placebo-controlled, randomized clinical trial. Ultrasonography was used to diagnose fatty liver in patients with alanine aminotransferase (ALT) >31 mg/dl and 41 mg/dl and aspartate aminotransferase (AST) >31 mg/dl and 47 g/dl in women and men, respectively and without other hepatic diseases. A total of 80 participants (20-50 years) with NAFLD were randomly allocated into two groups to receive either green tea extract (GTE) supplement (500 mg GTE tablet per day) or placebo for 90 days. At baseline and at the end of the intervention weight, serum ALT, AST, and alkaline phosphatase (ALP) were measured in fasting state, and dietary data were collected at baseline and end of the study. Results: Green tea group showed significant reductions in ALT and AST levels after 12 weeks period (P < 0.001). The placebo group showed a reduction in ALT and AST levels at the end of the study, but it was no significant. ALP levels showed significant reductions in both groups after 12 weeks period (P < 0.001). Conclusions: According to the findings of this study, GTE supplementation decrease liver enzymes in patients with NAFLD. It can be claimed that GTE prescribed can be considered as a treatment to improve serum levels of liver enzymes in NAFLD patients.

16 March 2020 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
MHMotahar Heidari‐Beni
Motahar Heidari‐Beni
AMAmir Reza Moravejolahkami
Amir Reza Moravejolahkami
PGPegah Gorgian
Pegah Gorgian
GAGholamreza Askari
Gholamreza Askari
MTMohammad J. Tarrahi
Mohammad J. Tarrahi
NBNimah Bahreini‐Esfahani
Nimah Bahreini‐Esfahani

1 February 2023 in Advances in Nutrition
Verified
Journal Article
Open access
AGAbed Ghavami
Abed Ghavami
RZRahele Ziaei
Rahele Ziaei
STSepide Talebi
Sepide Talebi
HBHanieh Barghchi
Hanieh Barghchi
ENElyas Nattagh-Eshtivani
Elyas Nattagh-Eshtivani
GAGholamreza Askari
Gholamreza Askari
To present a comprehensive synthesis of the effect of soluble fiber supplementation on blood lipid parameters in adults, a systematic search was undertaken in PubMed, Scopus, and ISI Web of Science of relevant articles published before November 2021. Randomized controlled trials (RCTs) evaluating the effects of soluble fibers on blood lipids in adults were included. We estimated the change in blood lipids for each 5 g/d increment in soluble fiber supplementation in each trial and then calculated the mean difference (MD) and 95% CI using a random-effects model. We estimated dose-dependent effects using a dose-response meta-analysis of differences in means. The risk of bias and certainty of the evidence was evaluated using the Cochrane risk of bias tool and the Grading Recommendations Assessment, Development, and Evaluation methodology, respectively. A total of 181 RCTs with 220 treatment arms (14,505 participants: 7348 cases and 7157 controls) were included. There was a significant reduction in LDL cholesterol (MD: −8.28 mg/dL, 95% CI: −11.38, −5.18), total cholesterol (TC) (MD: −10.82 mg/dL, 95% CI: −12.98, −8.67), TGs (MD: −5.55 mg/dL, 95% CI: −10.31, −0.79), and apolipoprotein B (Apo-B) (MD: −44.99 mg/L, 95% CI: −62.87, −27.12) after soluble fiber supplementation in the overall analysis. Each 5 g/d increase in soluble fiber supplementation had a significant reduction in TC (MD: −6.11 mg/dL, 95% CI: −7.61, −4.61) and LDL cholesterol (MD: −5.57 mg/dl, 95% CI: −7.44, −3.69). In a large meta-analysis of RCTs, results suggest that soluble fiber supplementation could contribute to the management of dyslipidemia and the reduction of cardiovascular disease risk.